Bavarian Nordic hunts for best covid-19 vaccine production setup – may drop current manufacturer

If Bavarian Nordic successfully takes its covid-19 vaccine to the market, it will need to produce a lot of doses. The company cannot currently complete this task, and is looking for ways to secure its production – without guaranteeing a renewed contract with its current partner AGC Biologics.

Photo: Bavarian Nordic / PR

Bavarian Nordic cannot exclusively handle production of the company's covid-19 vaccine if and when it is ready for phase III and the subsequent commercialization.

In spite of expansions made in the firm's production apparatus in recent years, the firm lacks the equipment and capacity necessary for fulfilling production in this scale, which Bavarian Nordic Chief Financial Officer Henrik Juuel tells MedWatch in an interview.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs